TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of “Buy” from Brokerages

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have been assigned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $10.3333.

HURA has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Wednesday, October 8th. Maxim Group lowered their price target on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Finally, Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in HURA. Geode Capital Management LLC grew its stake in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares in the last quarter. New York State Common Retirement Fund bought a new position in TuHURA Biosciences in the 2nd quarter worth $97,000. Marshall Wace LLP purchased a new position in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $79,000. Vanguard Group Inc. boosted its stake in TuHURA Biosciences by 1.6% during the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after acquiring an additional 35,426 shares in the last quarter. Finally, Brighton Jones LLC bought a new stake in TuHURA Biosciences in the third quarter worth $69,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Stock Down 6.0%

Shares of TuHURA Biosciences stock opened at $0.96 on Tuesday. The stock has a market cap of $49.38 million, a PE ratio of -1.93 and a beta of -0.03. The business has a fifty day simple moving average of $2.11 and a 200 day simple moving average of $2.44. TuHURA Biosciences has a 12 month low of $0.93 and a 12 month high of $5.50.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.